Format

Send to

Choose Destination
Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):9616-9621. doi: 10.1073/pnas.1807915115. Epub 2018 Sep 5.

Clinical and veterinary trypanocidal benzoxaboroles target CPSF3.

Author information

1
The Wellcome Trust Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, DD1 5EH Dundee, United Kingdom.
2
Anacor Pharmaceuticals, Inc., Palo Alto, CA 94303.
3
The Wellcome Trust Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, DD1 5EH Dundee, United Kingdom; d.horn@dundee.ac.uk.

Abstract

African trypanosomes cause lethal and neglected tropical diseases, known as sleeping sickness in humans and nagana in animals. Current therapies are limited, but fortunately, promising therapies are in advanced clinical and veterinary development, including acoziborole (AN5568 or SCYX-7158) and AN11736, respectively. These benzoxaboroles will likely be key to the World Health Organization's target of disease control by 2030. Their mode of action was previously unknown. We have developed a high-coverage overexpression library and use it here to explore drug mode of action in Trypanosoma brucei Initially, an inhibitor with a known target was used to select for drug resistance and to test massive parallel library screening and genome-wide mapping; this effectively identified the known target and validated the approach. Subsequently, the overexpression screening approach was used to identify the target of the benzoxaboroles, Cleavage and Polyadenylation Specificity Factor 3 (CPSF3, Tb927.4.1340). We validated the CPSF3 endonuclease as the target, using independent overexpression strains. Knockdown provided genetic validation of CPSF3 as essential, and GFP tagging confirmed the expected nuclear localization. Molecular docking and CRISPR-Cas9-based editing demonstrated how acoziborole can specifically block the active site and mRNA processing by parasite, but not host CPSF3. Thus, our findings provide both genetic and chemical validation for CPSF3 as an important drug target in trypanosomes and reveal inhibition of mRNA maturation as the mode of action of the trypanocidal benzoxaboroles. Understanding the mechanism of action of benzoxaborole-based therapies can assist development of improved therapies, as well as the prediction and monitoring of resistance, if or when it arises.

KEYWORDS:

CPSF73; N-myristoyltransferase; Ysh1; drug discovery; genetic screening

PMID:
30185555
PMCID:
PMC6156652
DOI:
10.1073/pnas.1807915115
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

The authors declare no conflict of interest.

Publication types, MeSH terms, Substances, Grant support

Publication types

MeSH terms

Substances

Grant support

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center